Livforsakringsbolaget Skandia Omsesidigt Has Trimmed Rockwell Collins (COL) Position; Fate Therapeutics (FATE) Sentiment Is 0.73

August 3, 2017 - By Maria Brooks

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $109.72 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Livforsakringsbolaget Skandia Omsesidigt decreased Rockwell Collins Inc (COL) stake by 76.03% reported in 2016Q4 SEC filing. Livforsakringsbolaget Skandia Omsesidigt sold 119,906 shares as Rockwell Collins Inc (COL)’s stock rose 9.83%. The Livforsakringsbolaget Skandia Omsesidigt holds 37,798 shares with $3.51M value, down from 157,704 last quarter. Rockwell Collins Inc now has $18.81 billion valuation. The stock rose 3.06% or $3.44 reaching $115.8. About 3.50M shares traded or 169.23% up from the average. Rockwell Collins, Inc. (NYSE:COL) has risen 16.15% since August 3, 2016 and is uptrending. It has underperformed by 0.55% the S&P500.

Livforsakringsbolaget Skandia Omsesidigt increased Intel Corp (NASDAQ:INTC) stake by 474,511 shares to 528,370 valued at $19.16 million in 2016Q4. It also upped Dominion Resources Inc/Va (NYSE:D) stake by 19,710 shares and now owns 34,822 shares. Allergan Plc was raised too.

Among 19 analysts covering Rockwell Collins (NYSE:COL), 11 have Buy rating, 1 Sell and 7 Hold. Therefore 58% are positive. Rockwell Collins had 45 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Tuesday, July 25 with “Hold”. The stock of Rockwell Collins, Inc. (NYSE:COL) has “Buy” rating given on Monday, September 21 by Canaccord Genuity. Jefferies maintained the shares of COL in report on Monday, July 24 with “Hold” rating. The firm has “Sell” rating given on Tuesday, August 1 by Goldman Sachs. Canaccord Genuity downgraded the stock to “Hold” rating in Tuesday, July 26 report. The stock of Rockwell Collins, Inc. (NYSE:COL) has “Buy” rating given on Monday, January 23 by Seaport Global. The firm has “Hold” rating by Jefferies given on Wednesday, April 19. The firm has “Buy” rating given on Friday, July 28 by Cowen & Co. RBC Capital Markets maintained it with “Outperform” rating and $101 target in Monday, September 21 report. The firm earned “Buy” rating on Monday, December 5 by Deutsche Bank.

Investors sentiment increased to 1.24 in 2016 Q4. Its up 0.07, from 1.17 in 2016Q3. It increased, as 42 investors sold COL shares while 150 reduced holdings. 94 funds opened positions while 145 raised stakes. 99.34 million shares or 1.33% more from 98.04 million shares in 2016Q3 were reported. Ls Invest Lc stated it has 5,103 shares or 0.03% of all its holdings. Caxton LP stated it has 80,000 shares or 0.34% of all its holdings. Mason Capital Mngmt Llc invested in 1.28% or 261,892 shares. Timber Hill Ltd Liability Co stated it has 0.01% of its portfolio in Rockwell Collins, Inc. (NYSE:COL). Nuance Invs Ltd Llc holds 1.04% of its portfolio in Rockwell Collins, Inc. (NYSE:COL) for 134,219 shares. Moreover, Jane Street Limited Liability Corporation has 0.03% invested in Rockwell Collins, Inc. (NYSE:COL). Howe And Rusling Inc has invested 0% in Rockwell Collins, Inc. (NYSE:COL). Daiwa Securities has invested 0% in Rockwell Collins, Inc. (NYSE:COL). Underhill Investment Mgmt Ltd reported 1.4% of its portfolio in Rockwell Collins, Inc. (NYSE:COL). Farr Miller Washington Limited Liability Com Dc accumulated 214,392 shares. Asset Mgmt One Com reported 0.05% in Rockwell Collins, Inc. (NYSE:COL). Weatherly Asset Mngmt L P, California-based fund reported 2,683 shares. Jpmorgan Chase And invested in 35,314 shares. Mawer Inv Ltd invested in 0.18% or 187,452 shares. Sigma Planning invested in 3,109 shares or 0.03% of the stock.

Since March 13, 2017, it had 0 buys, and 16 selling transactions for $8.04 million activity. MAHONEY COLIN R also sold $1.39M worth of Rockwell Collins, Inc. (NYSE:COL) on Monday, March 20. Shares for $284,232 were sold by STURGELL ROBERT A. Ortberg Robert Kelly also sold $1.86 million worth of Rockwell Collins, Inc. (NYSE:COL) on Monday, March 20. ALLEN PATRICK E also sold $393,520 worth of Rockwell Collins, Inc. (NYSE:COL) on Tuesday, March 14. On Monday, March 13 the insider STENSKE DOUGLAS E sold $226,780. The insider JASPER PHILIP J sold 7,311 shares worth $710,702. 770 shares were sold by NIEUWSMA DAVID J, worth $76,061 on Tuesday, March 14.

About 103,357 shares traded. Fate Therapeutics Inc (FATE) has risen 166.12% since August 3, 2016 and is uptrending. It has outperformed by 149.42% the S&P500.

Analysts await Fate Therapeutics Inc (NASDAQ:FATE) to report earnings on August, 14. They expect $-0.25 EPS, up 13.79% or $0.04 from last year’s $-0.29 per share. After $-0.24 actual EPS reported by Fate Therapeutics Inc for the previous quarter, Wall Street now forecasts 4.17% negative EPS growth.